Democracy in Science [0.03%]
科学领域的民主精神
Paolo Angeli
Paolo Angeli
Tailoring allocation policies and improving access to pediatric liver transplantation in Italy: Outframing and concluding [0.03%]
意大利儿童肝移植的分配政策调整及访问改善：框架构建与结论
Jean de Ville de Goyet
Jean de Ville de Goyet
Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Need a closer look!' [0.03%]
《乙型肝炎表面抗原血清转换后肝细胞癌的风险预测模型：需要进一步审视！》的回复
Hyun Yang,Jeong Won Jang
Hyun Yang
From the experimental to the clinical: Deepening the understanding of mycophenolate mofetil combined with prednisolone therapy [0.03%]
从实验到临床：深化对霉酚酸酯联合泼尼松治疗的理解
Yixuan Xu,Xiaofei Yu,Yongmei Guo
Yixuan Xu
Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis [0.03%]
随机试验：安纳金拉加锌与强的松对严重酒精相关性肝炎的对比研究
Samer Gawrieh,Srinivasan Dasarathy,Wanzhu Tu et al.
Samer Gawrieh et al.
Background & aims: Severe alcohol-associated hepatitis (SAH) is associated with high 90-day mortality. Glucocorticoid therapy for 28 days improves 30- but not 90-day survival. We assessed the efficacy and safety of a comb...
Randomized Controlled Trial
Journal of hepatology. 2024 May;80(5):684-693. DOI:10.1016/j.jhep.2024.01.031 2024
Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition [0.03%]
来自中东和北非以及撒哈拉以南非洲的关于继续支持代谢相关脂肪性肝病定义的联合立场声明
Yasser Fouad,Hasmik Ghazinyan,Mohamed Alboraie et al.
Yasser Fouad et al.
One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis [0.03%]
失代偿期肝硬化的最新定义揭示了一个或多个盲点
Florent Artru,Thomas Reiberger
Florent Artru
Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models [0.03%]
嵌合抗原受体修饰的巨噬细胞改善了临床前模型中的肝纤维化
Hanren Dai,Cheng Zhu,Qian Huai et al.
Hanren Dai et al.
Background & aims: Treatments directly targeting fibrosis remain limited. Given the unique intrinsic features of macrophages and their capacity to engraft in the liver, we genetically engineered bone marrow-derived macrop...
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies [0.03%]
用布列维蒂德阻断病毒进入可减少人类肝脏活检中的感染HDV的肝细胞的数量
Lena Allweiss,Annika Volmari,Vithika Suri et al.
Lena Allweiss et al.
Background & aims: Bulevirtide (BLV) is a first-in-class entry inhibitor and the only approved treatment for patients chronically infected with HDV in Europe. We aimed to investigate the efficacy of BLV treatment in paire...
Clinical Trial
Journal of hepatology. 2024 Jun;80(6):882-891. DOI:10.1016/j.jhep.2024.01.035 2024